CN101019875A

CN101019875A - Application of sophorolipid in preparing antibiotic medicine

Info

Publication number: CN101019875A
Application number: CN 200710013200
Authority: CN
Inventors: 宋欣; 曲音波; 邵凌健
Original assignee: Shandong University
Current assignee: Shandong University
Priority date: 2007-01-29
Filing date: 2007-01-29
Publication date: 2007-08-22

Abstract

The present invention discloses the application of sophorolipid or composition with sophorolipid as effective component in preparing antibiotic, especially in preparing antibiotic medicine for inhibiting cadida albicans and gram positive bacteria. The present invention prepares sophorolipid through fermentation, and the preparation process has the features of simplicity, low cost and high product purity. The sophorolipid and the composition with sophorolipid as effective component have high bacteriostasis effect and no toxic side effect.

Description

Application of sophorolipid in preparing antibiotic medicine

Technical Field

The invention relates to application of sophorolipid in preparing antibiotic medicaments, in particular to application of sophorolipid in preparing antibiotic medicaments for inhibiting candida albicans or gram positive bacteria.

Background

Abuse of antibiotics has become a significant problem worldwide over the last several decades. Besides causing adverse drug reactions and increasing treatment cost, the harm of abuse of antibiotics mainly enhances the drug resistance of bacteria, and China enters the straight-rising period of the drug resistance of bacteria. The current research shows that the penicillin resistance ratio of staphylococcus aureus in China is as high as 90%, the drug resistance ratio of pneumonia germs in community specimens is about 20%, and the drug resistance ratio in hospital specimens can reach 60%. Streptococcus pneumoniae is 45% resistant to penicillin and 70% resistant to erythromycin. Coli causing intestinal diseases is 70% ciprofloxacin resistant. The overuse of antibiotics renders many antibiotics ineffective.

The cost of developing a new antibiotic is in the order of billions of dollars and a 10 to 15 year process, and when improperly used, the pathogen will develop resistance to the drug in 3 to 5 years, and if this trend is not stopped, we will soon have no effective weapon against harmful microorganisms such as bacteria, and many small diseases can be fatal. Therefore, the research, development and protection of new antibiotics are urgent tasks and have important significance.

Sophorolipid is an important biosurfactant, and its research began in the fifth and sixty years of the twentieth century and was mainly obtained by microbial fermentation. Compared with a chemically synthesized surfactant, the sophorolipid has the advantages of excellent surface performance, environmental friendliness and the like.

In recent years, many documents have been reported for the foreign research on sophorolipids as clinical drugs, and the research on the bacteriostatic action of sophorolipids is also mentioned, but according to the literature and patent search, no report is found on the research and development of sophorolipids as antibiotic drugs for inhibiting candida albicans and gram positive bacteria.

Disclosure of Invention

Aiming at the serious problem that the microbial drug resistance is increasingly enhanced due to the clinical abuse of antibiotics at present and the urgent need for research and development of new antibiotics, the invention aims to solve the problem of providing the application of biosurfactant sophorolipid in preparing antibiotic medicaments, in particular the application of sophorolipid in preparing antibiotic medicaments for inhibiting candida albicans or gram positive bacteria.

The sophorolipid provided by the invention is applied to the preparation of antibiotic drugs.

In the application of the sophorolipid in preparing antibiotic medicaments, the sophorolipid is preferably applied in preparing antibiotic medicaments for inhibiting candida albicans.

Wherein, the final concentration of the antibiotic drug for effective bacteriostasis is 20-60 mg/L, preferably 20-50 mg/L, and most preferably 20-40 mg/L.

Or,

in the application of the sophorolipid in preparing antibiotic medicaments, the sophorolipid is preferably applied in preparing antibiotic medicaments for inhibiting gram-positive bacteria.

Wherein, the final concentration of the antibiotic drug for effective bacteriostasis is 20-100 mg/L, preferably 20-80 mg/L, and most preferably 20-50 mg/L.

The invention also comprises the application of the composition taking sophorolipid as an effective component in preparing antibiotic medicaments.

The sophorolipid can be added with pharmaceutically acceptable auxiliary materials or excipients to prepare any one of the pharmaceutically acceptable dosage forms.

The sophorolipid is used as an effective component, and is added with a bacteriostatic component and pharmaceutically acceptable auxiliary materials or excipients to form a bacteriostatic pharmaceutical composition, and the sophorolipid can also be prepared into any one of the dosage forms in pharmaceutics.

In the application of the sophorolipid in preparing antibiotic medicaments, the sophorolipid is one of oral preparations, suppositories, ointments and liquid preparations in preparing antibiotic medicaments for inhibiting candida albicans.

Wherein, the oral preparation is preferably one of capsules, tablets, powder, oral liquid, granules, water pills and dropping pills; most preferably capsules or tablets; the liquid formulation is preferably a liquid lotion.

In the application of the sophorolipid in preparing antibiotic medicaments, the sophorolipid is preferably an oral preparation in preparing antibiotic medicaments for inhibiting gram-positive bacteria.

Wherein, the oral preparation is preferably one of capsules, tablets, powder, oral liquid, granules, water pills and dropping pills; most preferably capsules or tablets.

The above suppositories, ointments, pharmaceutical preparations for oral administration can be prepared according to the methods known in the art, and the tablets can be coated according to the methods known in the art using pharmaceutically acceptable diluents in the preparation process, for example, binders (such as pregelatinized starch, polyvinylpyrrolidone or hydroxypropylcellulose), fillers (such as lactose, sucrose, mannitol, etc.), lubricants (such as stearic acid, polyethylene glycol, magnesium stearate, talc or silicon dioxide), disintegrants (such as starch, sodium carboxymethylcellulose) or wetting agents (such as sodium lauryl sulfate).

In order to better understand the essence of the present invention, the application of sophorolipids as an antibiotic drug for inhibiting candida albicans or gram positive bacteria is described below by the pharmacological experiments and results of sophorolipids.

Preparation of sophorolipid:

(1) selecting strains: souphorolipidCGMCC No.1576, a variation of Saccharomyces pseudovictimus, Wickerhamiella domercqiae var;

(2) slant culture: inoculating the strain into a basic inorganic salt culture medium, adding agar with the mass volume ratio of 1.5-2.0%, and performing static culture for 24-48 hours at the temperature of 25-35 ℃;

(3) seed culture: inoculating the strain cultured in the step (2) to a ring with an inoculation ring of 1-2 rings in 20-100 mL of a basic inorganic salt culture medium containing 4-14% of glucose and 1-8% of rapeseed oil in a mass-volume ratio under an aseptic condition, and performing shaking culture at 25-35 ℃ for 24-48 hours to prepare a seed solution;

(4) and (3) amplification culture: inoculating 5-10% of the inoculation amount by volume into 100-1000 mL of a basic inorganic salt culture medium containing 4-14% of glucose and 1-8% of rapeseed oil by mass volume, and performing shake culture at 25-35 ℃ for 96-288 hours;

(5) collecting a fermentation product: standing the fermentation liquor obtained in the step (4), naturally settling, collecting light yellow viscous liquid deposited at the bottom of a shake flask, centrifuging the viscous substance at 4000-7000 r/min, and collecting a precipitate; namely, the sophorolipid crude extract is obtained;

(6) and (3) separating a product: adding ethyl acetate with the volume amount of 3-10 times of that of the precipitate obtained by centrifugation, and extracting for 2-8 hours at the temperature of 25-37 ℃;

(7) and (3) filtering: filtering the ethyl acetate extract by Whatman No.2 filter paper at 25-37 ℃, and collecting filter residues;

(8) washing: washing the filter residue obtained in the step (3) for 2-4 times by using ethyl acetate with the volume amount of 3-10 times at 25-37 ℃;

(9) and (3) reduced pressure distillation: after washing, collecting filter residues, and keeping the temperature at 50-70 ℃ and the pressure at 0.2-0.8 Kg/cm²Carrying out reduced pressure distillation under the condition that the vacuum degree is 0.02-0.08 Mpa, and evaporating and removing ethyl acetate in the filtrate;

(10) and (3) drying the collected material: and (3) carrying out vacuum drying on the collected reduced pressure distillation residues for 12-24 hours at the temperature of 50-100 ℃ and the vacuum degree of 0.02-0.08 Mpa to prepare the solid sophorolipid.

Preparation of Candida albicans thallus:

transferring one loop of candida albicans preserved on the inclined plane into a liquid YEPD culture medium, and culturing for 10-20 hours at 25-37 ℃ to prepare a bacterial suspension.

Preparation of gram-positive bacteria (Staphylococcus aureus and Bacillus cereus):

transferring one loop of gram-positive bacteria preserved on the inclined plane into a liquid LB culture medium, and culturing for 10-20 hours at 25-37 ℃ to prepare a bacterial suspension.

Candida albicans bacteriostasis test:

dissolving sophorolipid with dimethyl sulfoxide to obtain mother liquid.

Adding the sophorolipid mother liquor into a YEPD liquid culture medium to enable the final concentration to be 20-60 mg/L, inoculating 0.8mL of the candida albicans suspension into 80mL of YEPD liquid culture medium, culturing at 25-37 ℃ for 6-24 hours, measuring the OD value of the culture solution at the wavelength of 560-620, and drawing a bacteriostasis curve by taking the OD value as the number of bacteria in the culture solution as the ordinate and time as the abscissa.

Gram-positive bacteria bacteriostasis test:

dissolving sophorolipid with dimethyl sulfoxide to obtain mother liquid.

Adding the sophorolipid mother liquor into an LB liquid culture medium to enable the final concentration to be 20-100 mg/L, inoculating 0.8mL of the gram-positive bacteria (staphylococcus aureus and bacillus cereus) suspension into 80mL of the liquid LB culture medium, culturing at 25-37 ℃ for 6-24 hours, determining the OD value of the culture solution at the wavelength of 560-620 nm, taking the OD value as the number of bacteria in the culture solution as the ordinate, and taking the time as the abscissa to draw the bacteriostasis curve.

In the Candida albicans bacteriostasis test, the final concentration of sophorolipid is preferably 20-50 mg/L, the culture temperature is preferably 28-32 ℃, the culture time is preferably 6-15 hours, and the OD value measurement wavelength is 580-600 nm.

In the gram-positive bacteria bacteriostasis test, the final concentration of sophorolipid is preferably 20-80 mg/L, the culture temperature is preferably 28-32 ℃, the culture time is preferably 8-18 hours, and the OD value determination wavelength is 580-600 nm.

The formula of the culture medium is as follows:

YEPD medium (g/L) (for Candida albicans culture): yeast extract 10, peptone 20, glucose 20, ph 6.5.

LB medium (g/L) (for gram-positive bacteria culture): peptone 10, yeast extract 5, NaCl10, pH 7.4.

The results show that:

the growth of candida albicans can be completely inhibited by extremely low dosage of sophorolipid within a short action time (less than 24 hours) (see figure 1), and compared with the matrine which has the best clinical effect of inhibiting candida albicans at present, the dosage of sophorolipid (20mg/L) is 1/1000 of the latter dosage (20g/L), and the cost of sophorolipid is only one tenth of that of matrine.

The study on gram-positive bacteria shows that the sophorolipid can completely inhibit the growth of staphylococcus aureus and bacillus cereus under the condition that the sophorolipid concentration is 50 mg/L. (see FIG. 2, FIG. 3)

The invention utilizes pseudo-wilk yeast variant to ferment and produce sophorolipid, and has the characteristics of simple and convenient process method, low cost and high purity.

The sophorolipid has the advantages of low price, small dosage, obvious antibacterial effect and no toxic or side effect on human bodies in the application of preparing antibiotic medicaments. The compound can be developed into clinical external lotion, ointment, suppository or oral preparation and other pharmaceutical dosage forms, can effectively inhibit the growth of clinically common opportunistic pathogenic bacteria candida albicans and some gram positive bacteria, can be completely used as antibiotic substitute medicines even in certain aspects, and has a very attractive application prospect.

Drawings

FIG. 1 inhibition curves of sophorolipids against Candida albicans

It was shown that the sophorolipid concentration at 20mg/L was able to completely inhibit the growth of Candida albicans.

FIG. 2 inhibition curves of sophorolipid against Staphylococcus aureus

It was shown that the sophorolipid concentration at 50mg/L was able to completely inhibit the growth of Staphylococcus aureus.

FIG. 3 shows the inhibition curve of sophorolipid against Bacillus cereus

It was revealed that the sophorolipid concentration at 20mg/L could completely inhibit the growth of Bacillus cereus.

Detailed Description

The present invention will be further described with reference to the following examples.

Example 1: preparation of sophorolipid

(1) Selecting strains: vickers pseudovar (Wickerhamiella domercqiae var. Sophorolipid) CGMCC No. 1576:

(2) slant culture: inoculating the strain in a basic inorganic salt culture medium, adding agar with the mass volume ratio of 1.6%, and performing static culture at 25 ℃ for 24 hours;

(3) seed culture: inoculating 1-2 rings of the strains cultured in the step (2) into 20mL of culture medium containing 4% of glucose and 1% of rapeseed oil in a mass-volume ratio under an aseptic condition, and performing shaking culture at 25 ℃ for 24 hours to prepare a seed solution;

(4) and (3) amplification culture: inoculating the seed solution into 100mL of a culture medium containing 1% of rapeseed oil by mass-volume ratio according to the inoculation amount of 5% by volume, and performing shaking culture at 25 ℃ for 96 hours;

(5) collecting a fermentation product: and (4) standing the fermentation liquor obtained in the step (4), naturally settling, collecting light yellow viscous liquid deposited at the bottom of a shake flask, centrifuging the viscous substance at 5000 r/min, and collecting a solid part, namely the sophorolipid crude extract.

(6) And (3) ethyl acetate extraction: ethyl acetate was added in an amount of 5 times by volume to the precipitate obtained by the above centrifugation, and the mixture was extracted at 30 ℃ for 4 hours.

(7) And (3) filtering: the ethyl acetate extract was filtered through Whatman No.2 filter paper at 30 ℃ to collect the residue.

(8) Washing: the residue obtained above was washed 3 times with ethyl acetate of 5 times by volume at 30 ℃.

(9) And (3) reduced pressure distillation: collecting filter residue after washing, and keeping the temperature at 70 deg.C and the pressure at 0.4kg/cm²Distilling under reduced pressure with vacuum degree of 0.04Mpa, and evaporating ethyl acetate in the filtrate;

(10) and (3) drying the collected material: vacuum drying the collected vacuum distillation residue at 70 deg.C under 0.04Mpa for 16 hr; preparing solid sophorolipid.

Example 2: preparation of sophorolipid

(2) slant culture: inoculating the strain in a basic inorganic salt culture medium, adding agar with the mass volume ratio of 1.6%, and performing static culture at 30 ℃ for 36 hours;

(3) seed culture: inoculating 1-2 rings of the strains cultured in the step (2) into 50mL of culture medium containing 8% of glucose and 3% of rapeseed oil in a mass-volume ratio under an aseptic condition, and performing shaking culture at 30 ℃ for 36 hours to prepare a seed solution;

(4) and (3) amplification culture: inoculating the seed solution into 500mL of a culture medium containing 3% by mass and volume of rapeseed oil according to the inoculation amount of 7% by volume, and performing shaking culture at the temperature of 30 ℃ for 200 hours;

(5) collecting a fermentation product: and (3) standing the fermentation liquor obtained in the step (4), naturally settling, collecting a light yellow viscous liquid deposited at the bottom of the shaking flask, centrifuging the viscous substance at 6000 rpm, and collecting a solid part which is a sophorolipid crude extract.

(6) And (3) separating a product: ethyl acetate was added in an amount of 7 times by volume to the precipitate obtained by the above centrifugation, and the mixture was extracted at 37 ℃ for 6 hours.

(7) And (3) filtering: the ethyl acetate extract was filtered through Whatman No.2 filter paper at 37 ℃ and the residue was collected.

(8) Washing: the residue obtained above was washed 3 times with ethyl acetate in an amount of 7 times by volume at 37 ℃.

(9) And (3) reduced pressure distillation: collecting filter residue after washing, and keeping the temperature at 70 ℃ and the pressure at 0.8kg/cm²Distilling under reduced pressure with vacuum degree of 0.08Mpa, and evaporating ethyl acetate in the filtrate;

(10) and (3) drying the collected material: vacuum drying the collected vacuum distillation residue at 100 deg.C under 0.08Mpa for 24 hr; preparing solid sophorolipid.

Example 3: application of sophorolipid as antibiotic medicine for inhibiting candida albicans

Preparation of Candida albicans thallus:

transferring one loop of Candida albicans preserved on the inclined plane into a liquid YEPD culture medium, and culturing at 25 ℃ for 20 hours to prepare a bacterial suspension.

Dissolving sophorolipid with dimethyl sulfoxide to obtain mother liquor with concentration of 5g/L for use.

Adding sophorolipid mother liquor into YEPD liquid culture medium to make its final concentration be 20mg/L, taking 0.8mL of the above-mentioned candida albicans suspension and inoculating it into 80mL of YEPD liquid culture medium, culturing at 25 deg.C for 24 hr, measuring OD value of culture solution under the wavelength 580, using OD value to express number of bacteria in the culture solution as ordinate, and using time as abscissa to draw bacteriostasis curve. And (5) detecting the bacteriostatic condition of the candida albicans test.

Example 4: application of sophorolipid as antibiotic medicine for inhibiting candida albicans

Preparation of Candida albicans thallus:

transferring one loop of candida albicans preserved on the inclined plane into a liquid YEPD culture medium, and culturing for 15 hours at 30 ℃ to prepare a bacterial suspension.

Adding sophorolipid mother liquor into YEPD liquid culture medium to make its final concentration be 30mg/L, taking 0.8mL of the above-mentioned candida albicans suspension and inoculating it into 80mL of YEPD liquid culture medium, culturing at 30 deg.C for 10 hr, measuring OD value of culture solution under the wavelength 590, using OD value to express number of bacteria in the culture solution as ordinate, and using time as abscissa to draw bacteriostasis curve. And (5) detecting the bacteriostatic condition of the candida albicans test.

Example 5: application of sophorolipid as antibiotic medicine for inhibiting candida albicans

Preparation of Candida albicans thallus:

transferring one loop of Candida albicans preserved on the inclined plane into a liquid YEPD culture medium, and culturing at 37 ℃ for 10 hours to prepare a bacterial suspension.

Adding sophorolipid mother liquor into YEPD liquid culture medium to make its final concentration be 50mg/L, taking 0.8mL of the above-mentioned candida albicans suspension and inoculating it into 80mL of YEPD liquid culture medium, culturing at 32 deg.C for 15 hr, measuring OD value of culture solution under the wavelength of 600, using OD value to express number of bacteria in the culture solution as ordinate, and using time as abscissa to draw bacteriostasis curve. And (5) detecting the bacteriostatic condition of the candida albicans test.

The formula of the YEPD culture medium is as follows: 10g/L of yeast extract, 20g/L of peptone, 20g/L of glucose and pH 6.5.

Example 6: application of sophorolipid as antibiotic medicine for inhibiting gram-positive bacteria

Preparation of staphylococcus aureus thallus:

transferring one loop of gram-positive bacteria preserved on the inclined plane into a liquid LB culture medium, and culturing at 25 ℃ for 20 hours to prepare a bacterial suspension.

Gram-positive bacteria bacteriostasis test:

dissolving sophorolipid with dimethyl sulfoxide to obtain mother liquid.

Adding sophorolipid mother liquor into LB liquid culture medium to make its final concentration be 20mg/L, taking 0.8mL of above-mentioned gram-positive bacteria (staphylococcus aureus) bacterial suspension and inoculating it into 80mL of liquid LB culture medium, culturing at 28 deg.C for 20 hr, measuring OD value of culture solution under the wavelength of 580nm, using OD value to represent number of bacteria in the culture solution as ordinate, and using time as abscissa to draw bacteriostatic curve. And (5) detecting the bacteriostatic condition of the sophorolipid.

Example 7: application of sophorolipid as antibiotic medicine for inhibiting gram-positive bacteria

Preparation of Bacillus cereus:

transferring one loop of gram-positive bacteria preserved on the inclined plane into a liquid LB culture medium, and culturing at 29 ℃ for 15 hours to prepare a bacterial suspension.

Gram-positive bacteria bacteriostasis test:

dissolving sophorolipid with dimethyl sulfoxide to obtain mother liquid.

Adding sophorolipid mother liquor into LB liquid culture medium to make its final concentration be 50mg/L, taking 0.8mL of above-mentioned gram-positive bacteria (Bacillus cereus) suspension and inoculating into 80mL of liquid LB culture medium, culturing at 30 deg.C for 12 hr, measuring OD value of culture solution under wavelength 590nm, using OD value to express number of bacteria in culture solution as ordinate, and using time as abscissa to draw bacteriostasis curve. And (5) detecting the bacteriostatic condition of the sophorolipid.

Example 8: application of sophorolipid as antibiotic medicine for inhibiting gram-positive bacteria

Preparation of staphylococcus aureus thallus:

Gram-positive bacteria bacteriostasis test:

dissolving sophorolipid with dimethyl sulfoxide to obtain mother liquid.

Adding sophorolipid mother liquor into LB liquid culture medium to make its final concentration be 80mg/L, taking 0.8mL of above-mentioned gram-positive bacteria (staphylococcus aureus) bacterial suspension and inoculating it into 80mL of liquid LB culture medium, culturing at 32 deg.C for 18 hr, measuring OD value of culture solution under the wavelength of 600nm, using OD value to express number of bacteria in the culture solution as ordinate, and using time as abscissa to draw bacteriostatic curve. And (5) detecting the bacteriostatic condition of the sophorolipid.

The LB culture medium formula is as follows: 10g/L of peptone, 5g/L of yeast extract, 10g/L of NaCl and 7.4 pH.

Example 9: preparation of antibiotic medicine suppository using sophorolipid for treating candida albicans infection

Taking 40g of sophorolipid prepared in example 1, and directly dissolving the sophorolipid into heated and melted glyceryl palmitoleate in a mixing amount of 50mg of sophorolipid per suppository, uniformly mixing, and then adding a suppository mold hole which is lubricated by a lubricant prepared by 1 part of soap and 1 part of glycerol and 5 parts of 90% ethanol in advance for forming to obtain the sophorolipid suppository. Each suppository contains sophorolipid 50 mg.

Example 10: preparation of sophorolipid as antibiotic medicine ointment for treating candida albicans infection

Adding liquid paraffin 125g into sophorolipid 40g prepared in example 1, heating to 80 deg.C, adding glycerol 50g and ethylparaben 1g, adding distilled water to 835g, heating to 80 deg.C, adding oil phase into water phase, stirring while cooling, and packaging into plastic hose with a packaging amount of 25g per tube to obtain sophorolipid ointment.

Example 11: preparation of sophorolipid as liquid lotion of antibiotic medicine for treating candida albicans infection

40g of the sophorolipid prepared in example 1 was added to 1000g of dimethyl sulfoxide to dissolve the sophorolipid, and the solution was filled in a 100mL plastic bottle.

Example 12: preparation of oral capsule of sophorolipid as antibiotic medicine for treating gram-positive bacteria infection

Weighing 7 parts of sophorolipid and 13 parts of excipient (starch) by weight (kilogram). Mixing sophorolipid with excipient according to the weight portion, drying, preparing into powder, sieving to obtain fine powder, and filling into gelatin hard capsules, wherein the filling amount of each capsule is 0.143 g. Wherein each capsule contains sophorolipid 0.05g and excipient (starch) 0.093 g.

The taking method of the capsule comprises the following steps: 2-3 granules each time, three times daily.

Example 13: preparation of suppository containing sophorolipid as effective component and used as antibiotic medicine

Taking 40g of sophorolipid prepared in example 1 and 100g of matrine, and directly dissolving the sophorolipid and matrine in the heated and melted palmitoleic acid glyceride in the mixing amount of 50mg of sophorolipid and 125mg of matrine in each suppository, and uniformly mixing. Then adding lubricant prepared by 1 part of soap, 1 part of glycerin and 5 parts of 90% ethanol in advance into the suppository mold hole for molding, thus obtaining the suppository. Each suppository contains sophorolipid 50mg and matrine 125 mg.

Example 14: animal experiments with sophorolipids

The sophorolipid antibiotic liquid lotion prepared in example 11 as a medicine for treating candida albicans infection was used for animal experiments.

60 mice were harvested, and a small incision was made in the axilla of the right anterior limb of each mouse and inoculated with Candida albicans. After 24h, samples were taken from the wound for microscopic observation and 45 mice were found to be infected with Candida albicans. Mice were divided into 9 groups, 5 groups were treated and rubbed with the sophorose lipid liquid preparation three times a day, and the other 4 groups were negative control groups and rubbed with physiological saline the same number of times. The administration is continued for 10 days. Wound healing was observed in the treated and control groups, and samples were taken from the wounds of the treated and control groups, respectively, and cultured using YEPD plates in which yeast was cultured.

From the experimental results, no colonies appeared in the treatment groups within 24h, and between 24h and 48h, only sporadic colonies appeared in the plates of the 5 treatment groups, and the average colony number was 3. The control group had a large number of colonies within 24h and could not be counted.

Claims

1. The sophorolipid is used in preparing antibiotic medicine.

2. The use of sophorolipids according to claim 1 in the preparation of an antibiotic medicament, wherein the sophorolipids are used in the preparation of an antibiotic medicament for inhibiting candida albicans.

3. The use of claim 2, wherein the antibiotic drug concentration is 20-60 mg/L.

4. The use of claim 2, wherein the antibiotic pharmaceutical dosage form is one of an oral formulation, a suppository, an ointment, and a liquid formulation.

5. The use of claim 4, wherein the oral formulation is a capsule or tablet.

6. The use of sophorolipids according to claim 1 in the preparation of an antibiotic medicament, wherein the sophorolipids are used in the preparation of an antibiotic medicament for inhibiting gram-positive bacteria.

7. The use of claim 6, wherein the antibiotic drug concentration is 20-100 mg/L.

8. The use of claim 6, wherein the antibiotic dosage form is an oral formulation.

9. The use of claim 8, wherein the oral formulation is a capsule or tablet.

10. Application of composition containing sophorolipid as effective component in preparing antibiotic medicine is disclosed.